Last reviewed · How we verify

AmDerma — Portfolio Competitive Intelligence Brief

AmDerma pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Econazole Nitrate Cream 1% Econazole Nitrate Cream 1% phase 3 Imidazole antifungal Lanosterol 14α-demethylase (CYP51) Dermatology / Infectious Disease
Econazole Nitrate Foam 1% Econazole Nitrate Foam 1% phase 3 Imidazole antifungal Lanosterol 14α-demethylase (CYP51) Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  2. Aesculape CRO Belgium BV · 1 shared drug class
  3. Bausch Health Americas, Inc. · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. Fakultas Kedokteran Universitas Indonesia · 1 shared drug class
  6. Galderma R&D · 1 shared drug class
  7. Hayat Abad Medical Complex, Peshawar · 1 shared drug class
  8. Jamaica Hospital Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AmDerma:

Cite this brief

Drug Landscape (2026). AmDerma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amderma. Accessed 2026-05-13.

Related